Zevra Therapeutics (ZVRA) Expected to Announce Quarterly Earnings on Monday

Zevra Therapeutics (NASDAQ:ZVRA) is projected to announce its Q4 2025 results after the market closes on Monday, March 9th. Analysts expect the company to announce earnings of $0.05 per share and revenue of $28.0530 million for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Monday, March 9, 2026 at 4:30 PM ET.

Zevra Therapeutics Price Performance

ZVRA opened at $8.98 on Friday. The company has a quick ratio of 8.57, a current ratio of 8.62 and a debt-to-equity ratio of 0.46. The company’s 50-day moving average price is $8.80 and its 200 day moving average price is $9.07. Zevra Therapeutics has a fifty-two week low of $6.19 and a fifty-two week high of $13.16. The firm has a market cap of $505.57 million, a price-to-earnings ratio of 19.11 and a beta of 0.91.

Analysts Set New Price Targets

A number of analysts have recently weighed in on ZVRA shares. Weiss Ratings reiterated a “sell (d+)” rating on shares of Zevra Therapeutics in a research report on Friday, January 9th. HC Wainwright set a $26.00 price objective on Zevra Therapeutics in a research report on Tuesday, December 30th. Finally, Wall Street Zen upgraded Zevra Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Zevra Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $22.80.

Insider Activity

In other Zevra Therapeutics news, SVP Timothy J. Sangiovanni sold 3,000 shares of the company’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $9.18, for a total value of $27,540.00. Following the completion of the transaction, the senior vice president owned 29,590 shares in the company, valued at approximately $271,636.20. This represents a 9.21% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Joshua Schafer sold 10,500 shares of Zevra Therapeutics stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $9.19, for a total value of $96,495.00. Following the sale, the insider directly owned 62,278 shares in the company, valued at approximately $572,334.82. This trade represents a 14.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 114,158 shares of company stock valued at $1,062,878. Company insiders own 2.40% of the company’s stock.

Institutional Trading of Zevra Therapeutics

Several hedge funds have recently added to or reduced their stakes in ZVRA. Millennium Management LLC boosted its position in Zevra Therapeutics by 9.6% during the 4th quarter. Millennium Management LLC now owns 1,134,358 shares of the company’s stock worth $10,164,000 after acquiring an additional 99,107 shares during the period. Man Group plc increased its holdings in shares of Zevra Therapeutics by 174.4% during the fourth quarter. Man Group plc now owns 92,347 shares of the company’s stock valued at $827,000 after purchasing an additional 58,695 shares during the period. Engineers Gate Manager LP raised its stake in shares of Zevra Therapeutics by 23.4% during the fourth quarter. Engineers Gate Manager LP now owns 44,020 shares of the company’s stock valued at $394,000 after purchasing an additional 8,359 shares in the last quarter. Schonfeld Strategic Advisors LLC bought a new stake in shares of Zevra Therapeutics during the fourth quarter valued at about $124,000. Finally, AQR Capital Management LLC lifted its holdings in Zevra Therapeutics by 18.9% in the fourth quarter. AQR Capital Management LLC now owns 181,129 shares of the company’s stock worth $1,623,000 after purchasing an additional 28,818 shares during the period. Institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.